Comparsion of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a two arm open label phase III clinical trial. Adult patients with hematological
malignancies undergoing allogeneic HSCT from any donor are eligible for the study if they
meet the standard criteria defined in the investigator's institutional standard operation
procedures (SOPs), meet all inclusion criteria, and do not satisfy any exclusion criteria.
Patients will receive reduced-intensity conditioning regimen of fludarabine, busulfan
(treosulfan). Patients will receive PTCy at different dose (25 mg/kg/day vs 50 mg/kg/day on
day +3,+4 in combination with calcineurin inhibitors and mofetil mycophenolate) as GvHD
prophylaxis.